ERBB2 and breast cancer: The same group has reported that the combination of emodin (20 μM) and paclitaxel (1 μM) synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu-overexpressing MDA-MB-361, BT-474, MDA-MB-231, and MDA-MB-435 BC cells in vitro.